Chevy Chase Trust Holdings LLC Has $202.34 Million Stake in Johnson & Johnson (NYSE:JNJ)

Chevy Chase Trust Holdings LLC decreased its position in Johnson & Johnson (NYSE:JNJ) by 5.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,399,101 shares of the company’s stock after selling 77,760 shares during the period. Johnson & Johnson makes up 0.6% of Chevy Chase Trust Holdings LLC’s holdings, making the stock its 25th biggest holding. Chevy Chase Trust Holdings LLC owned about 0.06% of Johnson & Johnson worth $202,338,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of JNJ. Asset Planning Inc acquired a new position in shares of Johnson & Johnson during the fourth quarter valued at about $795,000. Vicus Capital increased its position in shares of Johnson & Johnson by 1.9% during the fourth quarter. Vicus Capital now owns 5,464 shares of the company’s stock worth $790,000 after acquiring an additional 104 shares in the last quarter. Banque Pictet & Cie SA increased its position in shares of Johnson & Johnson by 10.7% during the fourth quarter. Banque Pictet & Cie SA now owns 178,474 shares of the company’s stock worth $25,811,000 after acquiring an additional 17,282 shares in the last quarter. V Square Quantitative Management LLC increased its position in shares of Johnson & Johnson by 3.9% during the fourth quarter. V Square Quantitative Management LLC now owns 47,319 shares of the company’s stock worth $6,843,000 after acquiring an additional 1,778 shares in the last quarter. Finally, CFC Planning Co LLC bought a new stake in shares of Johnson & Johnson during the fourth quarter worth about $1,920,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Activity at Johnson & Johnson

In other news, Director Mark A. Weinberger bought 1,000 shares of the stock in a transaction on Thursday, December 12th. The shares were acquired at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the purchase, the director now directly owns 1,000 shares of the company’s stock, valued at $147,220. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Stock Down 0.7 %

Johnson & Johnson stock opened at $156.20 on Tuesday. The company has a market capitalization of $376.08 billion, a P/E ratio of 23.49, a P/E/G ratio of 2.46 and a beta of 0.52. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The firm has a 50 day moving average price of $147.87 and a 200-day moving average price of $155.95. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $168.85.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. Johnson & Johnson’s revenue was up 5.3% compared to the same quarter last year. During the same period in the prior year, the company posted $2.29 EPS. As a group, equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.18%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s payout ratio is currently 74.59%.

Analyst Ratings Changes

Several research firms have recently commented on JNJ. Barclays boosted their target price on shares of Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a research report on Tuesday, January 28th. Raymond James decreased their target price on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Wells Fargo & Company decreased their target price on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research report on Thursday, January 23rd. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Finally, Argus raised shares of Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. Nine investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $170.67.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.